Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Type 1 helper T (Th1) cells are a specialized lineage of CD4+ effector T lymphocytes essential for host defense against intracellular pathogens (StatPearls, NBK541030). They are characterized by the production of interferon-gamma (IFN-γ), which activates macrophages and promotes cell-mediated immunity (Nature Reviews Immunology, 2006). The differentiation of Th1 cells is primarily driven by interleukin-12 (IL-12) and the master transcription factor T-bet (UniProt, Q9JKD8). These cells play a critical role in the elimination of viruses and bacteria that reside within host cells. While vital for clearing infections, excessive or dysregulated Th1 activity is a hallmark of several autoimmune and inflammatory disorders, such as Crohn's disease and rheumatoid arthritis (PubMed, 11911823). In these conditions, Th1-mediated inflammation leads to tissue damage and chronic disease progression. Therapeutic strategies targeting Th1 cells include the use of monoclonal antibodies like ustekinumab, which inhibits the IL-12 signaling required for Th1 development (NCBI, PMC3135093). Other approaches involve neutralizing Th1-derived cytokines or using broad immunosuppressants to reduce T-cell activation. Conversely, in oncology, enhancing Th1 responses is a goal of certain immunotherapies to improve anti-tumor immunity.
Inhibition of Th1 differentiation via IL-12/IL-23 antagonism, neutralization of Th1-secreted cytokines such as IFN-gamma and TNF-alpha, or broad suppression of T-cell receptor signaling and proliferation.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Type 1 helper T cell (Th1) (Th1).